Over the past 15 years, comparative assessments of psychoactive substance harms to both users and others have been compiled by addiction experts. None of these rankings however have included synthetic cannabinoids or non-opioid prescription analgesics (NOAs, e.g., gabapentinoids) despite evidence of increasing recreational use. We present here an updated assessment by German addiction medicine experts, considering changing Western consumption trends-including those of NOAs. In an initial survey, 101 German addiction medicine physicians evaluated both physical and psychosocial harms (in 5 dimensions) of 33 psychoactive substances including opioids and NOAs, to both users and others. In a second survey, 36 addiction medicine physicians estimated the relative weight of each health and social harm dimension to determine the overall harm rank of an individual substance. We compared our ranking with the most recent European assessment from 2014. Illicit drugs such as methamphetamine, heroin, cocaine and also alcohol were judged particularly harmful, and new psychoactive drugs (cathinones, synthetic cannabinoids) were ranked among the most harmful substances. Cannabis was ranked in the midrange, on par with benzodiazepines and ketamine-somewhat more favorable compared to the last European survey. Prescribed drugs including opioids (in contrast to the USA, Canada, and Australia) were judged less harmful. NOAs were at the bottom end of the ranking. In Germany, alcohol and illicit drugs (including new psychoactive substances) continue to rank among the most harmful addictive substances in contrast to prescribed agents including opioid analgesics and NOAs. Current laws are incongruent with these harm rankings. This study is the first of its kind to include comparative harm rankings of several novel abused substances, both licit/prescribed and illicit.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649209 | PMC |
http://dx.doi.org/10.3389/fpsyt.2020.592199 | DOI Listing |
Emerg Med Australas
February 2025
Addiction Psychiatry and Toxicology, Northern Health, Melbourne, Victoria, Australia.
Serotonin toxicity is a potentially fatal condition caused by increased serotonergic activity in the central nervous system. Cyproheptadine, a serotonergic antagonist, is recommended for treatment; however, there is a lack of evidence to support its use. The present study aimed to evaluate the evidence for the use of cyproheptadine in the management of serotonin toxicity following deliberate self-poisoning.
View Article and Find Full Text PDFCureus
December 2024
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, IND.
Background The synthetic opioid tramadol is widely used as a pain reliever. Unlike other opioids, it is used freely worldwide, unaffected by international controls resulting in abuse and accidental intoxication. Analytical methods are necessary to prove tramadol abuse because 30% of the drug is excreted unchanged.
View Article and Find Full Text PDFHCA Healthc J Med
December 2024
Del Sol Medical Center, El Paso, Texas.
Background: Addiction affects millions of people, often resulting from a complex interplay between genetic and environmental factors, and is frequently linked to mental health disorders. Many experts agree there is no cure for addiction, but there are effective treatments available. Many patients continue to succumb to addiction despite treatment.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
June 2023
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
Addiction
January 2025
Center for Health Systems Effectiveness, Department of Emergency Medicine, Oregon Health and Science University, Portland, OR, USA.
Background And Aims: Medication is the gold standard to support a healthy pregnancy for pregnant people with opioid use disorder (OUD). This study measured inequities and differences in OUD medication treatment among pregnant people in Oregon, USA.
Design, Setting, Participants And Measurements: Our study population consisted of Medicaid enrollees across the US state of Oregon who had at least one live hospital birth between 2012 and 2020 and one diagnosis of OUD prenatally (n = 4363).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!